The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? [Globe and Mail, The (Toronto, Canada)]
MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
Company Research
Source: Globe and Mail, The
The sale represented 4.9% of Mr. Santos da Silva's direct holdings, reducing his directly held position to 2,924,893 shares as of April 13, 2026. The transaction was executed directly by Mr. Santos da Silva; there were no indirect holdings or derivative securities involved. Chief Executive Officer Jorge Santos da Silva reported the sale of 150,000 shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) through multiple open-market transactions on April 10, 2026 and April 13, 2026, according to a SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value ~$2.8 million Post-transaction shares (direct) Post-transaction value (direct ownership) ~$53.9 million Transaction value based on SEC Form 4 weighted average purchase price ($18.35); post-transaction value based on April 13, 2026 market close price. Key questions How does the size of this transaction compare to Mr. Santos da Silva's past sales? This sale of 150,000 shares is ab
Show less
Read more
Impact Snapshot
Event Time:
MLTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLTX alerts
High impacting MoonLake Immunotherapeutics - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MLTX
News
- MoonLake Immunotherapeutics (MLTX) had its "buy" rating reaffirmed by BTIG Research. They now have a $30.00 price target on the stock.MarketBeat
- MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting [Yahoo! Finance]Yahoo! Finance
- MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual MeetingGlobeNewswire
- MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.MarketBeat
- MoonLake Immunotherapeutics (MLTX) was upgraded by Rothschild & Co Redburn from "neutral" to "buy". They now have a $40.00 price target on the stock.MarketBeat
MLTX
Earnings
- 2/25/26 - Miss
MLTX
Sec Filings
- 4/16/26 - Form 4
- 4/14/26 - Form 4
- 4/10/26 - Form 4
- MLTX's page on the SEC website